in perirenal adipose tissue and lungs was pyridalyl, accounting for greater than 90 and 60%, respectively, of the total, whereas a major metabolite in whole blood, kidneys, and liver was a dehalogenated metabolite. The experimental data were simulated with simple physiologically based pharmacokinetics using fourcompartment models with assumption of lymphatic absorption and membrane permeability in adipose tissues. The different kinetics in brown and white adipose tissues was reasonably predicted in this model, with large distribution volume in adipose tissues and high hepatic clearance in liver. Sex-related difference of pyridalyl concentration in liver was considered to be a result of different unbound fraction times the hepatic intrinsic clearance (f ؋ CL int ) of 1.8 and 12 l/h for male and female, respectively.
centration in tissues, and the metabolic fate were determined. Most 14 C was excreted into feces. The 14 C concentrations in the blood and tissues attained steady-state levels at days 6 to 10, whereas those in white adipose tissues increased until day 14. Tissue 14 C concentrations were highest in brown and white adipose tissue (38.37-57.50 ppm) but were 5.60 ppm or less in all the other tissues. Total 14 C residues in blood and tissues on the 27th day after the first administration accounted for 2.6 to 3.2% of the total dose. A major fecal metabolite resulted from O-dealkylation. Analysis of metabolites in tissues revealed that the majority of 14 C in perirenal adipose tissue and lungs was pyridalyl, accounting for greater than 90 and 60%, respectively, of the total, whereas a major metabolite in whole blood, kidneys, and liver was a dehalogenated metabolite. The experimental data were simulated with simple physiologically based pharmacokinetics using fourcompartment models with assumption of lymphatic absorption and membrane permeability in adipose tissues. The different kinetics in brown and white adipose tissues was reasonably predicted in this model, with large distribution volume in adipose tissues and high hepatic clearance in liver. Sex-related difference of pyridalyl concentration in liver was considered to be a result of different unbound fraction times the hepatic intrinsic clearance (f ؋ CL int ) of 1.8 and 12 l/h for male and female, respectively.
Pyridalyl is a new class of insecticide for Lepidoptera and Thysanoptera (Sakamoto et al., 2004; Isayama et al., 2005) . It has dichloropropenyl, dichlorophenyl, and pyridyl groups in its structure and does not share structural similarity with other insecticides. The mode of action of pyridalyl has not been determined; it has toxicity to insect cells. Toxicity studies in mammals, including acute, chronic, oncogenicity, developmental, mutagenicity, and reproductive studies, have all been previously conducted with low acute toxicity, no oncogenicity and mutagenicity, and no teratogenicity observed (US Environmental Protection Agency, 2008) .
In previous studies, metabolism of [dichlorophenyl-14 C]pyridalyl and [dichloropropenyl- 14 C]pyridalyl in rats was investigated in conjunction with a toxicological safety evaluation (Nagahori et al., 2009a,b) . After administration of [dichlorophenyl- 14 C]pyridalyl or [dichloropropenyl-14 C] pyridalyl to rats at 5 or 500 mg/kg, the radiocarbon was rapidly absorbed, and relatively high levels were apparent in adipose tissue.
14 C then was rapidly excreted mainly into feces (Ͼ99% of the dose) for [dichlorophenyl- 14 C]pyridalyl and feces (ϳ70%), urine (ϳ10%), and expired air (ϳ10%) for [dichloropropenyl- 14 C]pyridalyl. Ether cleavage was the major biotransformation reaction.
14 C concentrations decreased relatively slowly in adipose tissue and skin, and 14 C in adipose tissue was primarily accounted for by pyridalyl itself. To clarify the accumulation and decrease of pyridalyl in rat body, time course of 14 C concentration in tissues including brown and white fat during and after repeated oral administration of pyridalyl is measured. The high concentration in adipose tissue might have been caused by the lipophilic nature of pyridalyl (log P ϭ 8.1). Lipophilic compounds such as dieldrin, dichlorodiphenyltrichloroethane (DDT) [dichlorodiphenyldichloroethylene (DDE)], polychlorinated biphenyl (PCB), and tetrachlorodibenzodioxin (TCDD) are also known to become distributed to adipose tissue and eliminated slowly.
However, pyridalyl has a different nature. Residual 14 C in adipose tissue 7 days after administration of pyridalyl was 2% of the dose, in contrast to values for lipophilic compounds such as dieldrin, DDT (DDE), PCB, and TCDD of Ͼ6%, 53.03%, 50 to 70%, and 10 to 20%, respectively (Hayes, 1974; Matthews and Tuey, 1980; Abraham et al., 1988; Mühlebach et al., 1991) . Pyridalyl has an ether bond that is easily cleaved, whereas dieldrin, DDT (DDE), and PCB are more resistant to degradation. In the current study, we determined the rate and extent of 14 C accumulation in adipose tissue (brown and white fat) after repeated oral administration of pyridalyl, and the results were compared with other lipophilic compounds to clarify differences in accumulation properties.
Pyridalyl was rapidly metabolized to form S-1812-DP in liver after administration and then was excreted rapidly (Nagahori et al., 2009a) . To clarify the distribution profile and metabolic stability, physiologically based pharmacokinetic (PBPK) models are useful analytical tools. Therefore, we also used such a model for fitting the observed data, and model parameters were determined to quantitatively assess the pharmacokinetics of pyridalyl in rats. Relevant data for lipophilic compounds, such as TCDD, chlordecone, p,pЈ-DDE, and hexachlorobenzene, have been generated previously (Roth et al., 1993; Li et al., 1995; You et al., 1999; Evans and Andersen, 2000; Wang et al., 2000; Emond et al., 2004; Lu et al., 2006; Belfiore et al., 2007) , allowing direct comparison. Thus, the present report deals with metabolism ( 14 C excretion into feces, urine, expired air; 14 C concentrations in tissues including brown and white fat; and amounts of metabolites in excreta and tissue) of [dichlorophenyl-14 C]pyridalyl in male and female rats during and after repeated oral administration for 14 consecutive days at 5 mg/kg/day to determine the extent of accumulation and elimination of accumulated radioactivity. In addition, pyridalyl concentrations in tissues were analyzed by simple PBPK modeling to clarify the distribution property and metabolic stability of pyridalyl and to facilitate comparison with other lipophilic compounds.
Materials and Methods
Chemicals. [Dichlorophenyl- 14 C]pyridalyl was prepared at the Environmental Health Science Laboratory of Sumitomo Chemical, Co., Ltd. (Takarazuka, Japan) with a specific activity of 10.2 MBq/mg. Labeled compound was purified with thin-layer chromatography (TLC) before use, and the radiochemical purity was Ͼ98.8%. Unlabeled pyridalyl (purity, 99.7%) was also obtained from our company and analyzed by 64, 117, 131, 71, 31, 67, 112, 137 , and 146 ppm. Fast atom bombardment/mass spectrometry showed a molecular ion peak at m/z 490 [MϩH] ϩ . Authentic standards (S-1812 -DP, S-1812 -Py-OH, HPHM, and S-1812 were prepared at the Environmental Health Science Laboratory (Sumitomo Chemical, Co., Ltd.). All the other chemicals were reagent grade.
TLC Analysis. Identification and quantification of metabolites were conducted using a solvent system of hexane/toluene/acetic acid (3:15:2, v/v/v, developed twice). Unlabeled pyridalyl and authentic standards on TLC plates were detected by viewing under UV light (254 nm), and radioactive metabolites were noted by autoradiography using imaging plates processed with a BAS2000 Bioimage Analyzer (Fuji Photo Film, Kanagawa, Japan). Pyridalyl and S-1812-DP were isolated using the same solvent system for further identification by high-performance liquid chromatography (HPLC).
HPLC Analysis. Purification of isolated pyridalyl and S-1812-DP was conducted using an L-6200-type intelligent pump (Hitachi, Tokyo, Japan), an L-4000 UV detector (Hitachi), an LB 507A HPLC radioactivity monitor (Berthold, Bad Wildbad, Germany) , and an 805 data station (Japan Millipore Limited, Tokyo, Japan). The metabolites were purified using an octadecylsilane column (COSMOSIL, 4.6 mm i.d. ϫ 15 cm; Nacalai Tesque, Kyoto, Japan) and a guard column (Guard-Pak, Bondapak C18; Waters, Milford, MA) with mobile phases of acetonitrile/1% acetic acid in water (gradients: 0:100, 0 -5 min; 20:80, 10 -30 min; and 100:0, 35 min). The flow rate was 1.0 ml/min. Purified pyridalyl and S-1812-DP were identified by HPLC cochromatography with authentic standards using the same conditions as described above. The wavelength of the UV detector was set at 254 nm.
Radioanalysis. Radioactivity in organosoluble fractions or urine was quantified by liquid scintillation counting (LSC) giving disintegrations per minute by the external standard method with a Tri-Carb 2500TR Liquid Scintillation Analyzer (PerkinElmer Life and Analytical Sciences, Waltham, MA). Samples (100 -300 mg) of fecal homogenates, unextractable fecal residues, and tissues were combusted with a sample oxidizer (Tri-Carb 307; PerkinElmer Life and Analytical Sciences) before LSC after air-drying (combustion-LSC method). Quantification of radiocarbon on TLC plates was conducted with scraping methods.
Animal Treatment. Seven groups of three male and three female Crj:CD (Sprague-Dawley) rats at the age of 6 weeks were purchased from Charles River Japan Inc. (Kanagawa, Japan). All of the animal experiments were conducted in accordance with the Guidelines for Proper Conduct of Animal Experiments (Science Council of Japan). Animals that showed normal weight gain and no abnormal clinical symptoms during 7 days of quarantine and acclimation were selected for dosing. The in-life portion of the study was conducted under the following environmental conditions: room temperature, 20 to 26°C; relative humidity, 55 Ϯ 10%; ventilation, 10 air exchanges/h; and artificial lighting from 8:00 AM to 8:00 PM. Animals had free access to pelleted diet and water through the study. Seven groups (designated as groups A-G) of three male and three female rats were orally dosed [dichlorophenyl-14 C]pyridalyl (2.02 ϫ 10 7 dpm/mg) in corn oil at 5 ml/kg with 5 mg/kg/day for 1, 6, and 10 days for groups A to C, respectively, and 14 days for groups D to G and housed in aluminum cages or glass metabolism cages (only for group G).
Metabolism Study. The animals of the group G were used for metabolism studies. Feces and urine were separately collected daily to day 17 and once every 2 days thereafter (days 19 -27). After the collection of feces and urine, the cage was washed with water to recover 14 C (cage-wash samples). The urine and cage-wash samples were weighed, and then duplicate aliquots of each sample were radioassayed by LSC. Radioactivity in the cage-wash samples was included in the urinary excretion. The fecal samples of individual rats were separately homogenized with an approximately 3-fold volume of water, and then duplicate aliquots were combusted for radioanalysis.
Tissue Distribution Study. Rats were euthanized with collection of blood from the abdominal artery at 1 day after the last administration for groups A to C and after 1, 4, 7, and 14 days, respectively, for groups D to G. Their organs and tissues were dissected out, and plasma and blood cells were separated by centrifugation (2000g, 10 min). Blood was collected in plastic vials containing aliquots of heparin (Nacalai Tesque). An aliquot of collecting blood (approximately 1-3 g) was centrifuged at 2000g for 10 min at 4°C to separate the plasma from red blood cells. Duplicate aliquots of whole blood, plasma, red blood cells, and each tissue were measured by a combustion-LSC method. However, the average 14 C concentration in lungs of two female rats was used for day 6. The 14 C concentration in lungs of the third female rat on day 6 was not included because of a value approximately 10 times higher than those in all the other lungs of males and females.
Chromatographic Analysis of Metabolites. Equal percentages of 0-to 3-day fecal homogenates were pooled by sex and were mixed with an approximately 5-fold volume of acetone. The homogenates were centrifuged at 2000g for 10 min at 4°C. The supernatants were collected by decantation, and the precipitates were extracted twice with acetone. The residues from the acetone extraction were then extracted three times with a 5-fold volume of a mixture of methanol/water (9:1, v/v) in the manner described above. Each extract was combined and weighed, and then duplicate aliquots were radioassayed by LSC. Each residue was mixed with a 3-fold volume of water and weighed, and then duplicate aliquots were combusted to determine the extraction efficiency for 14 C in feces. The fecal homogenates for days 11 to 14 were processed similarly. The fecal and tissue extracts were concentrated and analyzed by TLC.
Equal percentages of 0-to 3-day urine were pooled by sex and analyzed by TLC. Urine from days 11 to 14 was processed similarly.
Blood (approximately 1 g) of each rat in the group D was pooled for each sex. Samples (approximately 0.3-0.5 g) of perirenal adipose tissue, kidneys,
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The metabolites on TLC plates were quantified by the scraping-LSC method. Radioactivity in areas where no discrete spot or band was detected on the TLC autoradiograms was included in "others." Urinary, fecal, and tissue metabolites were identified by TLC cochromatography with authentic standards. In addition, major fecal metabolites (pyridalyl and S-1812-DP) were isolated by TLC and identified by HPLC cochromatography with corresponding authentic standards.
PBPK Model Development. The model was based on data from two studies: an earlier single oral administration (Nagahori et al., 2009a ) and the present repeated oral administration of pyridalyl. The model structure included the blood, liver, white adipose tissue, brown adipose tissue, and the rest of body with assumption of lymphatic absorption and membrane permeability in adipose tissues (Fig. 1) . The general mass balance equation of the white (w) and brown adipose tissue (b) should be expressed as eq. 1: the mass balance for the concentrations, C x , is as follows:
where x stands for w, b, and r; t is time, V x is the volume of each compartment, Q x is the blood flow rate to each compartment, K x is the equilibrium distribution ratio, C a is the concentration in blood, P x is the permeability, and C x is the concentration in each compartment. In the rest of the body (r), the mass balance for the concentrations, C r , is
In the liver (l), the mass balance for the concentration, C l , is
where f is unbound fraction and CL int is the hepatic intrinsic clearance.
In the blood (a), the mass balance for the concentration, C a , is
where F is the absorption fraction, D is the oral dose, and k is the absorption rate. Pyridalyl concentrations in each compartment after single oral administration were calculated by the Runge-Kutta-Gill method (Hanano, 1987) . Pyridalyl concentrations in each compartment after repeated oral administration were calculated by a superposition technique with concentrations after the single oral administration.
Model parameters are shown in Table 1 . The absorption fraction, F, was experimentally set at 0.4 at first administration and 0.8 thereafter (see Discussion; absorption fraction becomes higher after repeated dose). Absorption fraction was calculated as follows using the amount of metabolites in excreta. Approximately 40% of 14 C in excreta was metabolites, and approximately 60% of 14 C was unchanged pyridalyl (Nagahori et al., 2009a) . Because unchanged pyridalyl in feces was considered to be unabsorbed pyridalyl and metabolites in excreta were formed in the body after absorption, absorption fraction after single oral administration was set at 0.4. Absorption fraction after repeated oral absorption was calculated with the same calculation using data in Table 5 . The values of equilibrium coefficient (K), absorption rate (k), permeability (P), and unbound fraction times the hepatic intrinsic clearance (f ϫ CL int ) were optimized by model fitting to the datasets as follows. The values of equilibrium coefficient (K) and absorption rate (k) were initially obtained from Table 6 and data of TCDD (Emond et al., 2004) , respectively, and permeability (P) was presumed from distribution and elimination rate of 14 C concentration in adipose tissues (Tables 2 and 3 of the present study). The 14 C concentration in adipose tissues was considered as the pyridalyl concentration because the majority of 14 C in adipose tissue was the result of pyridalyl itself. First, the combined parameter, unbound fraction times the hepatic intrinsic clearance (f ϫ CL int ), was optimized by model fitting to the datasets of 14 C concentration in adipose tissues and pyridalyl concentrations in liver and blood at the 14th day (Table 6 ) because unbound fraction and hepatic intrinsic clearance were not accurately determined as a result of low 14 C concentration of pyridalyl in blood. Then, K, k, P, and f ϫ CL int were refined and optimized sequentially several times using 14 C concentration and pyridalyl concentrations in adipose tissues, liver, and blood after repeated oral administration and corrected pyridalyl concentration calculated from 14 C concentration in the earlier study (Nagahori et al., 2009a) . Correction factors were used for calculation of corrected pyridalyl concentration in adipose tissues, liver, and blood using the equation: corrected pyridalyl concentration ϭ correction factor ϫ total 14 C concentration in tissues. Correction factors of adipose tissues, liver, and blood were 1, 0.3, and 0.3, respectively, for males and 1, 0.06, and 0.3, respectively, for females, derived from data in Table 6 . The optimized K and P are shown in Table 1 . The optimized absorption rate (k) was 0.05/h. Optimized unbound fraction times the hepatic intrinsic clearance (f ϫ CL int ) was 1.8 and 12 l/h for males and females, respectively.
Results

C Excretion.
Feces and urine were collected and radioassayed daily or once every 2 days during and after repeated oral administration of [dichlorophenyl- 14 C]pyridalyl at 5 mg/kg/day to male and female rats for 14 consecutive days. Profiles of 14 C administration and 14 C excretion into feces and urine were calculated as percentages of the total dose and are shown in Fig. 2 . Most 14 C was excreted into feces, accounting for 91.5 to 94.5% of the total dose within 27 days, with that excreted into urine representing 2.0 to 4.4% of the total dose. Total 14 C excretion within 27 days after first administration was approximately 96 to 97% of the total dose. The 14 C excretion showed no remarkable sex-related difference.
14 C Distribution to Blood and Tissues. Blood and tissues were collected and radioassayed at days 1, 6, 10, 14, 17, 20, and 27 . The 14 C concentrations in blood and tissues are shown in Tables 2 and 3 for males and females, respectively, and biological half-life times of 14 C in tissues of male and female rats are shown in Table 4 . The 14 C concentrations in blood and tissues, except for white adipose tissue (perirenal and testicular sites), generally increased in proportion with the number of administrations at days 1 to 6 or 1 to 10, and then reached a plateau. The 14 C concentrations in white adipose tissues increased until day 14. Adipose tissues (brown and white) showed the (Roth et al., 1993) and the volume fraction for the rest of the body were estimated from the total volume fraction of 91% (Emond et al., 2004) . b Values are from the previous literature (Roth et al., 1993) , including the percentage of cardiac output of the rest of the body (Emond et al., 2004) . c Values were initially obtained from Table 6 and then optimized by model fitting. 14 C concentrations in other tissues were relatively low (5.60 ppm or less). The 14 C concentrations in the tissues except for white adipose tissues generally showed biphasic decrease with biological half-lives of 1 to 5 days (␣ phase) and 4 to 24 days (␤ phase), whereas elimination from white adipose tissue was exponential with biological half-lives of 10 to 15 days. Total 14 C residues at day 27 after first administration were calculated as the sums of the radioactivity found in blood and tissues, accounting for 2.6 to 3.2% of the total dose. Total 14 C recovery in excreta, blood, and tissues was approximately 99% of the total dose. The 14 C concentrations in blood and tissues showed no remarkable sex-related difference.
Metabolites in Feces and Urine. The urine samples and fecal extracts were analyzed by TLC. Table 5 shows data for metabolite distribution as percentages of the total dose between days 0 to 3 and days 11 to 14. S-1812-DP was detected as the major metabolite, accounting for approximately 6 to 10% of the total dose. Other metabolites each accounted for less than 1% of the total dose. Pyridalyl excretion between days 0 and 3 was higher than that between days 11 and 14, accounting for approximately 7 to 8% and 5 to 6% of the total dose, respectively. The lower pyridalyl excretion at days 11 to 14 might indicate enhanced absorption with repeated oral doses. Absorption fractions (100, percentage of pyridalyl in excreta) were calculated to be approximately 60% for 0 to 3 days and 80% for 11 to 14 days. On the other hand, metabolite distribution shown as percentage of metabolites did not remarkably change between days 0 to 3 and days 11 to 14. No sex-related difference in the metabolite distribution was observed in males and females.
Metabolites in Tissues. Blood and tissue extracts were analyzed by TLC. Table 6 shows the metabolite distribution as microgram equivalents of pyridalyl in grams of tissue (ppm). The majority of 14 C in perirenal adipose tissue and lungs was pyridalyl, accounting for greater than 90 and 60% of the total radioactive residues, respectively, whereas S-1812-AA was the major metabolite in whole blood, kidneys, and liver. Although the pyridalyl concentration in liver was much lower in females, no other remarkable sex-related difference in the metabolite distribution was observed.
Simulation. Pyridalyl concentrations in adipose tissues, liver, and blood were reasonably predicted using a simple PBPK model shown in Fig. 1 and parameters shown in Table 1 and described under Figure 3 presents the model predictions of pyridalyl concentration in adipose tissue, liver, and blood and the corrected experimental data for 14 C concentrations in adipose tissue, liver, and blood of male and female rats after single oral administration of [dichlorophenyl- 14 C]pyridalyl at 5 mg/kg. Figure 4 presents the model predictions of pyridalyl concentration in adipose tissues, liver, and blood and the corrected experimental data for 14 C concentrations in adipose tissues and the pyridalyl concentrations in blood and liver of male and female rats during and after repeated oral administration of [dichlorophenyl- 14 C]pyridalyl at 5 mg/kg/day for 14 consecutive days. A large distribution volume in adipose tissues and high hepatic clearance in liver were important for precise prediction of pyridalyl concentration in each tissue. The prediction of the pyridalyl concentrations in adipose tissues reasonably agreed with the experimental data of 14 C in adipose tissues, considering the majority of 14 C in adipose tissues is pyridalyl. The different kinetics in brown and white adipose tissues was reasonably predicted in this model. The predicted pyridalyl concentrations in blood and liver were consistent with the experimental data. The remarkable sex-related difference in liver and the slight difference in adipose tissues were reasonably predicted using unbound fraction times hepatic intrinsic clearance (f ϫ CL int ) of 1.8 and 12 l/h in males and females, respectively.
Materials and Methods.
Discussion
In the present study of metabolic fate and tissue accumulation of [dichlorophenyl- 14 C]pyridalyl during and after repeated oral administration of [dichlorophenyl- 14 C]pyridalyl at 5 mg/kg/day to male and female rats daily for 14 consecutive days, the radiocarbon was rapidly absorbed, and 14 C concentrations showed differing profiles among white adipose, brown adipose, and other tissues. In all but the white adipose case a steady state was reached around days 6 to 10. In white adipose tissue, increase continued until day 14. The 14 C concentration in the white adipose tissues was relatively high (approximately 38 -43 ppm) and similar to that in brown adipose tissue (approximately 39 -58 ppm). However, 14 C concentrations in other tissues were relatively low (Ͻ5.60 ppm). The 14 C concentration in white adipose tissues decreased slowly after termination of dosing, whereas those in other tissues decreased biphasically and rapidly.
14 C was rapidly excreted into mainly feces, comparable with the earlier single oral dose study (Nagahori et al., 2009a) . Cumulative 14 C distribution at day 27 was 92 to 95%, 2 to 4%, and 3% of the total dose for feces, urine, and tissues, respectively, with total 14 C recoveries of 99%.
S-1812-DP was detected as the major metabolite in excreta, again in line with the single oral dose study (Nagahori et al., 2009a) . Small amounts of S-1812-Py-OH, HPHM, S-1812-AA, and other metabolites were detected in excreta. The majority of 14 C in perirenal adipose tissue and lungs was pyridalyl, whereas that in whole blood, kidneys, and liver was S-1812-AA. No marked sex-related differences were observed in 14 C elimination, the 14 C distribution, and the metabolite profile, except for liver pyridalyl concentration. The 14 C elimination (Ͼ90% of fecal excretion), the 14 C distribution (relatively high concentration in fat), and metabolite profile in excreta (mainly S-1812-DP) appear to be similar with single low, single high (Nagahori et al., 2009a) , and repeated oral administration schedules. In addition, pharmacokinetics were proportional to dose in both highdose (500 mg/kg) and low-dose (5 mg/kg) previous single oral dose studies (Nagahori et al., 2009a) . Thus, the results indicate that metabolism, distribution, and excretion of pyridalyl were not affected by increase of dose to 500 mg/kg or repeated doses. Only one difference was that fecal pyridalyl content was decreased with repeated oral administration. The results indicate that the absorption fraction increased with repeated oral administration. The absorption fraction with single oral dose was approximately 40% in the previous single oral dose study calculated from excreted fecal metabolites (Nagahori et al., 2009a) . With our repeated oral doses, the absorption fraction was estimated to be approximately 60 and 80% at 0 to 3 and 11 to 14 days, respectively, because the percentage of fecal pyridalyl considered unabsorbed was approximately 40 and 20% in 0-to 3-day and 11-to 14-day feces. The observed increase in the absorption fraction might have been caused by repeated administration of the vehicle, corn oil, which produces high concentrations of chylomicrons in the lymph (Cheema et al., 1987) . Increase of the absorption fraction after oil administration was also observed with other lipophilic chemicals, such as DDT (Palin et al., 1982) , which are absorbed via the lymphatic system. Although the absorption route of pyridalyl was not identified here, its lipophilicity and increase of absorption fraction suggest lymphatic absorption of pyridalyl. This would reasonably explain the rapid distribution of pyridalyl to tissues (fat) and blood without high levels in the liver. The 14 C distribution and elimination in white adipose tissue and brown adipose tissue were significantly different, although the highest 14 C concentrations in these tissues were similar. In our current results, brown adipose tissue showed the more rapid distribution and elimination. The difference appeared to be related to blood flow and Table 1 . The tissue volume of brown fat was smaller than that of white fat. The partition coefficient of pyridalyl in brown fat (P b ϭ 1000) was fitted to be only slightly lower than that of white fat (P w ϭ 1200). The partition of lipophilic compound in these tissues is reported to be controlled by lipid contents, and a lower partition coefficient in brown adipose tissue was also observed with TCDD (Roth et al., 1994) . Smaller distribution volume of brown fat is based on the smaller volume and lower partition coefficient of brown adipose tissue. Higher blood flow and smaller distribution volume could cause rapid distribution and elimination in brown fat. The same distribution profile was observed with lipophilic compounds, such as TCDD , but this is the first report for prediction of pharmacokinetics of more lipophilic and higher clearance compound using a simple PBPK model, including brown and white adipose tissues. The fact that 14 C concentrations decreased relatively slowly in adipose tissue might have been caused by the lipophilic nature of pyridalyl (log P ϭ 8.1). High lipophilicity of pyridalyl combined with C-concentration data in the previous study (Nagahori et al., 2009a) using the following correction factor. Correction factors of adipose tissues, liver, and blood were 1, 0.3, and 0.3, respectively, for males and 1, 0.06, and 0.3, respectively, for females (see Table 6 ).
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at ASPET Journals on June 24, 2017 dmd.aspetjournals.org a low blood flow rate in adipose tissue (0.1 l/h) might result in a high distribution volume. The current PBPK model of pyridalyl could simulate these pharmacokinetics, in agreement with experimental data for 14 C in white adipose tissues using a high partition coefficient (K w ϭ 1200) and high permeability (P w /Q w ϭ 1.3). Partition coefficient and permeability of pyridalyl are higher than those of other highly lipophilic compounds, such as TCDD, and the lipophilic nature might result in a prolonged time to steady state and a delayed biological half-life. High partition rate is consistent with the difference of pyridalyl concentration (approximately 1200 times) in adipose tissue and in blood at steady state (from Table 6 ), and high permeability is consistent with fast distribution of pyridalyl to adipose tissue within 1 day (Nagahori et al., 2009a) . The elimination rate from white fat calculated with the equation {P w / [K w ϫ V w ϫ (1 ϩ P w /Q w )]} (from eq. 1) was very low (0.0028/h) and was comparable with that published for TCDD (0.0016/h) (Emond et al., 2004) .
Although elimination from adipose tissue was slow, 14 C residues in tissue were low at approximately 3%. This value contrasts with values of Ͼ6%, 53.03%, 50 to 70%, and 10 to 20%, respectively, for lipophilic compounds such as dieldrin, DDT (DDE), PCB, and TCDD (Hayes, 1974; Matthews and Tuey, 1980; Abraham et al., 1988; Mühlebach et al., 1991) . Although elimination of these lipophilic compounds from adipose tissue was similar, relatively high residue of these compounds in adipose tissue might be the result of metabolic stability. Pyridalyl has an ether bond that is readily cleaved, whereas dieldrin, DDT (DDE), and PCB are more resistant to degradation. Pyridalyl is rapidly metabolized to form S-1812-DP in liver after administration and then seems to be excreted rapidly. In the current PBPK model, unbound fraction times the hepatic intrinsic clearance of pyridalyl was estimated to be 1.8 to 12 l/h, much higher than with other lipophilic compounds, such as chlordecone (0.005 l/h) (Belfiore et al., 2007) , DDT (DDE, 0 l/h) (You et al., 1999) , and hexachlorobenzene (0.00195 l/h) (Lu et al., 2006) . Hepatic clearance of pyridalyl was predominantly determined by hepatic blood flow (flow limited) and calculated to be 0.6 to 0.9 l/h with the equation [Q l ϫ f ϫ CL int / (Q l ϩ f ϫ CL int )]. This high hepatic intrinsic clearance of pyridalyl could have been responsible for the lower accumulation of pyridalyl in adipose tissues.
The simulated low pyridalyl concentration in blood (Ͻ0.1 ppm) is consistent with high hepatic clearance. Although the free fraction of pyridalyl in blood was not confirmed, it might be expected to be low because of the high partition coefficients in adipose tissue and liver. Low concentration of free pyridalyl resulted in low distribution of pyridalyl to tissues except fat and liver. One reason for low toxicity could be the high lipophilic nature of pyridalyl. When added to the fact that pyridalyl was rapidly metabolized and eliminated from the Tables 2 and 3 . Experimental pyridalyl concentrations in blood and liver were derived from Table 6 . -, simulated data.
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Although a marked sex-related difference was not observed in 14 C elimination and the 14 C distribution, pyridalyl concentrations in liver did markedly differ between males and females. In addition, slight sex variation was observed in 14 C concentrations in adipose tissue. These differences could be simulated with increase of unbound fraction times hepatic intrinsic clearance (f ϫ CL int ) in female rats from 1.8 to 12 l/h. Although the clearance was approximately 7 times higher than in males, the slight difference in 14 C concentrations in adipose tissue might be because blood flow limited hepatic clearance of pyridalyl. Difference in hepatic intrinsic clearances affected only hepatic pyridalyl concentrations. These differences presumably were related to reported variation in activity and expression of cytochrome P450, such as CYP2C12, CYP2C7, and CYP2A1, between the sexes (Pampori and Shapiro, 1999) . These enzymes could be involved in metabolism of pyridalyl. However, we have not yet conducted an in vitro metabolism study for identification of metabolizing enzyme, so this remains to be tested. Absorbed 14 C was rapidly eliminated into feces as S-1812-DP, an ether-cleaved metabolite of pyridalyl. The metabolic profile was almost the same as that in the single oral study. The hydroxyl group in S-1812-DP can be conjugated to form a glucuronide or sulfate in liver after absorption, and conjugated S-1812-DP is readily excreted into feces via the bile. S-1812-DP was detected as a major metabolite in excreta and was also the major form in the single oral dose study (Nagahori et al., 2009a) . Small amounts of S-1812-Py-OH, HPHM, S-1812-AA, and other metabolites were detected in excreta. The majority of 14 C in perirenal adipose tissue and lungs was pyridalyl, whereas that in whole blood, kidneys, and liver was S-1812-AA. Proposed metabolic pathways are shown in Fig. 5 .
